ArticleBlood advances2017
Cold agglutinin disease burden: a longitudinal analysis of anemia, medications, transfusions, and health care utilization.
Article in Blood advances, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- Trial
- Trial
- Cold agglutinin disease: pathophysiology, diagnosis, and the evolving therapeutic landscape.Blood research · 2026Review
- Bone Marrow Pathology in Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia: A Study of 56 Cases.European journal of haematology · 2026Article
- Real-World Use of Rituximab in the Treatment of Cold Agglutinin Disease in the United States: A Retrospective Study.EJHaem · 2025Article
- Efficacy of sutimlimab for cold agglutinin disease in a patient on chronic hemodialysis.CEN case reports · 2025Article
- A middle-aged woman with the initial symptom of acrocyanosis diagnosed with cold agglutinin disease: A case report.SAGE open medical case reports · 2025Article
- Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B.EClinicalMedicine · 2024Article
- Article
- Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up.Blood advances · 2023Article
- Cold AIHA and the best treatment strategies.Hematology. American Society of Hematology. Education Program · 2022Article
- An observational analysis of disease burden in patients with cold agglutinin disease: Results from a large US electronic health record database.Journal of managed care & specialty pharmacy · 2022Observational
- Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study.Annals of hematology · 2022Article
- The Burden of Cold Agglutinin Disease on Patients' Daily Life: Web-Based Cross-sectional Survey of 50 American Patients.JMIR formative research · 2022Article
- Updates on the Diagnosis and Management of Cold Autoimmune Hemolytic Anemia.Hematology/oncology clinics of North America · 2022Review
- Article
- Article
- Demographic characteristics, thromboembolism risk, and treatment patterns for patients with cold agglutinin disease in Japan.International journal of hematology · 2020Article
- Increased risk of thrombotic events in cold agglutinin disease: A 10-year retrospective analysis.Research and practice in thrombosis and haemostasis · 2020Article
- Cold agglutinin disease: current challenges and future prospects.Journal of blood medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cold agglutinin disease (CAD), a rare disease and subtype of autoimmune hemolytic anemia, is characterized by autoantibodies that bind to red blood cells at low temperatures. There is no established standard of care for CAD treatment and CAD cohort studies are limited by the rarity of the condition. The objectives of this study are to present the longitudinal experience of a CAD cohort from the United States, with a focus on anemia severity, use of medications and transfusions, and health care resource utilization. The Stanford Translational Research Integrated Database Environment database was used to retrospectively identify CAD patients diagnosed and treated at Stanford Health Care from 2000 to 2016. Twenty-nine patients were included in this analysis. There were 7.1 severe anemia events per patient-year observed over the follow-up time. For CAD patients treated at Stanford, there was a mean of 3.5 therapies per patient. Transfusions were given in at least 65% of the cohort with a mean of 11 transfusions per patient-year. For CAD-related health care use in the first year after disease onset, 93% used outpatient services with a median of 26 outpatient visits per patient. The data presented here likely represent the minimum number of events for these patients during this timeframe, as this single-center experience does not capture care from other providers. This longitudinal study of CAD patients demonstrates the severity of anemia and relapsing nature of the disease, even after administration of multiple therapies and transfusions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.